Recent Updates
Recently added Catalysts

Anktiva

Phase 2

Long COVID | Small molecule | Infectious Disease |ImmunityBio, Inc.|Last Updated: May 13, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDDMC
Total Trials1
Total Enrollment40

FDA Designations

BREAKTHROUGH_THERAPY

Clinical trial landscape

Anktiva · 1 trial · 3 indications

Phase 2 1
NCT07123727A Study to Examine Anktiva for the Treatment of COVID-19.Long COVID
RECRUITING40 Analytics
PHASE2RECRUITING
A Study to Examine Anktiva for the Treatment of COVID-19.
Long COVID
NCT0712372740
Unlock trial analytics

Study Endpoints

Primary Endpoints

Incidence of treatment emergent adverse events (TEAEs) through 30 days post final study drug administration.
Through 30 days post final study drug administration.
Incidence of grade 3 or higher TEAEs through 30 days post final study drug administration.
Through 30 days post final study drug administration.
Incidence of serious adverse events (SAEs) through 30 days post final study drug administration.
Through 30 days post final study drug administration.
Incidence of abnormal changes in safety laboratory tests (CBC and CMP).
Through the end of the study treatment period (approximately 75 days).
Clinically important changes in vital signs such as temperature in degrees Fahrenheit.
Through the end of the study treatment period (approximately 75 days).
Clinically important changes in vital signs such as heart rate in beats per minute.
Through the end of the study treatment period (approximately 75 days).
Clinically important changes in vital signs such as blood pressure in millimeters of mercury (mmHg).
Through the end of the study treatment period (approximately 75 days).
Clinically important changes in vital signs such as respiratory rate in breaths per minute.
Through the end of the study treatment period (approximately 75 days).
Clinically important changes in vital signs such as oxygen saturation in percentage.
Through the end of the study treatment period (approximately 75 days).

Secondary Endpoints

Percent increase or decrease change in the Absolute lymphocyte count (as measured on CBC) from Screening to End Of Study with various timepoints.
Through the end of the study treatment period (approximately 75 days).
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
N-803EXPERIMENTAL -

Interventions

NameTypeDescription
AnktivaDRUG600ug of NAI administered subcutaneously
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 70 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Age ≥ 18 and \< 70 years. * History of at least one SARS-CoV-2 infection, defined as report of a positive nucleic acid amplification test (NAAT) and/or a positive SARS-CoV-2 antigen rapid diagnostic test (RDT). Those with only suspected but unconfirmed infections are not eligi...

Countries:United States
Unlock Eligibility Criteria

Competitive Landscape -COVID-19 34 trials (matched to "Long COVID")

CompanyTickerTrialsLead PhaseDrugs
Pfizer Inc.PFE7PHASE3ibuzatrelvir, remdesivir
BioNTech SE Sponsored ADRBNTX1PHASE3BNT162b2 Vaccine
Merck & Co., Inc.MRK1PHASE3Molnupiravir
Invivyd, Inc.IVVD2PHASE3VYD2311-SD, VYD2311-MD
Vanda Pharmaceuticals Inc.VNDA1PHASE3Tradipitant
BioVie Inc. Class ABIVI1PHASE2NE3107
ImmunityBio IncIBRX2PHASE2Anktiva
Traws Pharma, Inc.TRAW1PHASE2Ratutrelvir non-randomised, Paxlovid, Ratutrelvir
GeoVax Labs, Inc.GOVX1PHASE2COVID-19 Vaccine, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1
Moderna, Inc.MRNA1 - SPIKEVAX Bivalent BA.1, SPIKEVAX XBB.1.5, SPIKEVAX JN.1
Abbott LaboratoriesABT1N/AUndisclosed
Design Therapeutics, Inc.DSGN1EARLY_PHASE1COVID-19 Therapeutic Biologic Mix- NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use
Jade Biosciences, Inc.JBIO1N/AUndisclosed
Structure Therapeutics, Inc. Sponsored ADRGPCR1N/AUndisclosed
Unlock Competitive Intelligence

Frequently asked questions about Anktiva

What is Anktiva used for in Long COVID?

Anktiva is an investigational small molecule being studied for the treatment of Long COVID, also referred to as Long COVID Syndrome or Long Covid 19. It is currently in Phase 2 clinical development and has not been approved by the FDA for this indication.

Who makes Anktiva?

Anktiva is being developed by ImmunityBio, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol IBRX. The company is conducting clinical research to evaluate Anktiva as a potential treatment for Long COVID.

What phase is Anktiva in for Long COVID?

Anktiva is in Phase 2 clinical development for Long COVID. It is an investigational drug, meaning it has not yet received FDA approval and is still being evaluated in clinical trials to determine its safety and effectiveness.

What clinical trials is Anktiva in?

Anktiva is being studied in a Phase 2 clinical trial with the identifier NCT07123727, titled 'A Study to Examine Anktiva for the Treatment of COVID-19.' The trial is currently recruiting participants in the United States and aims to enroll 40 adults aged 18 years and older.

Is Anktiva FDA approved?

Anktiva is not FDA approved for Long COVID. It is an investigational drug currently in Phase 2 clinical trials. The FDA has granted Anktiva Breakthrough Therapy designation, which is intended to expedite the development and review of drugs for serious conditions.